Completed PHASE3 INTERVENTIONAL 2-arm NCT01067365

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003

Sponsor: Repros Therapeutics Inc.

Conditions Secondary Hypogonadism

Interventions Androxal

Updated 7 times since 2017 Last updated: Jun 26, 2014 Started: Mar 31, 2006 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Secondary Hypogonadism, this trial is completed. The trial is conducted by Repros Therapeutics Inc. and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Repros Therapeutics Inc.

Data source: Repros Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Birmingham, United States , Carmichael, United States , Fort Wayne, United States , Hackensack, United States , Huntsville, United States , Las Vegas, United States , Lawrenceville, United States , Livonia, United States , Madisonville, United States and 7 more locations